Table 1.
Survival at One and Two Years with Ipilimumab and Glycoprotein Peptide 100 (gp100)Vaccine
| Ipilimumab plus gp 100 (N = 403) | Ipilimumab plus Placebo (N = 137) | gp100 plus Placebo (N = 136) | |
|---|---|---|---|
| At one year | 44% | 46% | 25% |
| At two years | 22% | 24% | 14% |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.